Participated · Series A · Aug 2026

Infinimmune uses its Anthrobody platform to screen millions of single memory B cells across hundreds of targets to identify naturally paired human antibodies, then applies its GLIMPSE antibody language models to guide optimisation for potency, specificity, half-life and developability. Its lead programmes are IFX-101, a monoclonal antibody targeting interleukin-22 described as a potential first-in-class candidate, and IFX-201, which targets interleukin-13 as a potential best-in-class option for atopic dermatitis. The company expects first-in-human studies for both programmes to begin in 2027 and is advancing additional antibody programmes derived from its human-first discovery approach. Financially, Infinimmune raised $75 million in a Series A co-led by Regeneron Ventures and Playground Global, and earlier support includes ongoing backing from Playground Global since founding. In March 2026 it entered a multi-target collaboration with Merck that includes up to about $838 million in upfront and potential milestone payments, which the company cites as validation of its platform and a potential commercial route.

Participated · Series A · Jun 2026

Syntax Bio develops a CRISPR-based Cellgorithm™ platform intended to program and accelerate stem cell differentiation to enable scalable cell therapies. The company is advancing a pancreatic beta cell therapy candidate for type 1 diabetes and plans to fund preclinical proof-of-concept studies with proceeds from its expanded Series A. Syntax Bio has publicly reported a collaboration with Mayo Clinic, received a grant from Breakthrough T1D, and published peer-reviewed research in Science Advances describing its technology. Financially, the company expanded its Series A to $14.4 million, bringing total funding to over $25 million. Leadership changes accompanying the financing include a CEO who joined in 2025 and new executive, board, and scientific advisory appointments to support translational development and commercialization. The company positions its platform as a way to replace slow, labor-intensive differentiation processes with a programmable approach to generate functional cells at scale.

Participated · Seed · Apr 2026

10x Science builds a platform that interprets complex mass spectrometry data using deterministic algorithms grounded in chemistry and biology alongside AI agents trained on spectrometry datasets. The product produces traceable analyses intended to meet regulatory-compliance needs and accelerate characterization of biologic drug candidates. The founders—David Roberts, Andrew Reiter, and Vishnu Tejas—came from a Stanford lab and trained the models to handle varied molecular data and explain their conclusions. 10x is currently working with major pharmaceutical companies, academic researchers, and service firms like Rilas Technologies. The company intends to use its $4.8M seed to hire engineers, further refine its models, and roll the platform out to more customers. No revenue, user, or valuation metrics were disclosed in the article.

Participated · Series A · Dec 2025

Trial Library operates an AI-enabled platform that connects biopharmaceutical manufacturers, payers, health systems, providers and patients to clinical trials offered as a standard care option. The technology activates community-based clinicians, identifies eligible patients compliantly, and guides them through the entire trial lifecycle. The company already supports more than 320 clinics and 1,500 providers nationwide, demonstrating meaningful early network scale. Led by founder and CEO Dr. Hala Borno, Trial Library positions itself as an accelerator of precision medicine uptake, working closely with self-insured and traditional health plans. Fresh capital is earmarked to deepen product development and broaden operational reach, enabling further clinic onboarding and payer partnerships. To date, the company has secured a total of $15 million in venture financing, underlining growing investor confidence in its model.

Participated · Series A · Oct 2025

Curve Biosciences positions itself as the “Whole-Body Intelligence” company focused on lowering the cost and improving the effectiveness of chronic disease management. Its core product suite pairs the Whole-Body Atlas—a manually curated repository said to be the world’s largest collection of tissue samples labeled by organ and disease state—with AI models to create Whole-Body Blood Tests that can anticipate disease onset and guide therapy choices. The resulting platform aims to give actionable insights to patients, insurers, pharmaceutical companies, and physicians. The company’s executive team includes veterans from Genentech, GRAIL, Natera, Counsyl, and Stanford University, bringing deep expertise in precision diagnostics, product development, and AI. Curve intends to use its newly raised capital to complete clinical validation studies and commercialize its tests. Financially, the company has secured $40 million in Series A funding and has not disclosed any revenue or user figures to date. With this capital, Curve Biosciences plans to scale both its data assets and blood-testing operations to support broader market adoption.